The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
Open accessAbstract
PURPOSE: We report the final, protocol-specified analysis of overall survival (OS) in GOG-0218, a phase III, randomized trial of bevacizumab in women with newly diagnosed ovarian, fallopian tube, or primary peritoneal carcinoma. METHODS: A total of 1,873 women with incompletely resected stage III to IV disease were randomly assigned 1:1:1 to six 21-day cycles of intravenous carboplatin (area under the concentration v time curve 6) and paclitaxel (175 mg/m 2 ) versus chemotherapy plus concurrent bevacizumab (15 mg/kg, cycles 2 to 6) versus chemotherapy plus concurrent and maintenance bevacizumab (cycles 2 to 22). Inclusion criteria included a Gynecologic Oncology Group performance status of 0 to 2 and no history of clinically significant vascular events or evidence of intestinal obstruction. OS was analyzed in the intention-to-treat population. A total of 1,195 serum and/or tumor specimens were sequenced for BRCA1/2 and damaging mutations in homologous recombination repair (HRR) genes. Intratumoral microvessel density was studied using CD31 immunohistochemistry. RESULTS: Median follow-up was 102.9 months. Relative to control (n = 625), for patients receiving bevacizumab-concurrent (n = 625), the hazard ratio (HR) of death was 1.06 (95% CI, 0.94 to 1.20); for bevacizumab-concurrent plus maintenance (n = 623), the HR was 0.96 (95% CI, 0.85 to 1.09). Disease-specific survival was not improved in any arm. No survival advantage was observed after censoring patients who received bevacizumab at crossover or as second line. Median OS for stage IV bevacizumab-concurrent plus maintenance was 42.8 v 32.6 months for stage IV control (HR, 0.75; 95% CI, 0.59 to 0.95). Relative to wild type, the HR for death for BRCA1/2 mutated carcinomas was 0.62 (95% CI, 0.52 to 0.73), and for non- BRCA1/2 HRR, the HR was 0.65 (95% CI, 0.51 to 0.85). BRCA1/2, HRR, and CD31 were not predictive of bevacizumab activity. CONCLUSION: No survival differences were observed for patients who received bevacizumab compared with chemotherapy alone. Testing for BRCA1/2 mutations and homologous recombination deficiency is essential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
Self-citationIncorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
Self-citationPocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L., & Montz, F. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1248 · Cited by 2,312
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., Sorio, R., Vergote, I., Witteveen, P., Bamias, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4489 · Cited by 1,622
Aghajanian, C., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., Sovak, M. A., Yi, J., & Nycum, L. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0505 · Cited by 1,384
Self-citationOza, A. M., Cook, A. D., Pfisterer, J., Embleton, A., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00086-8 · Cited by 875
Katsumata, N., Yasuda, M., Takahashi, F., Isonishi, S., Jobo, T., Aoki, D., Tsuda, H., Sugiyama, T., Kodama, S., Kimura, E., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61157-0 · Cited by 727
Coleman, R. L., Brady, M. F., Herzog, T. J., Sabbatini, P., Armstrong, D. K., Walker, J. L., Kim, B.-G., Fujiwara, K., Tewari, K. S., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30279-6 · Cited by 609
Self-citationWright, A. A., Bohlke, K., Armstrong, D. K., Bookman, M. A., Cliby, W. A., Coleman, R. L., Dizon, D. S., Kash, J. J., Meyer, L. A., Moore, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.6907 · Cited by 409
Self-citationPignata, S., Scambia, G., Katsaros, D., Gallo, C., Pujade-Lauraine, E., De Placido, S., Bologna, A., Weber, B., Raspagliesi, F., Panici, P. B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70049-x · Cited by 389
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
Chan, J. K., Brady, M. F., Penson, R. T., Huang, H., Birrer, M. J., Walker, J. L., DiSilvestro, P. A., Rubin, S. C., Martin, L. P., Davidson, S. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505067 · Cited by 367
Self-citationWright, A. A., Bohlke, K., Armstrong, D. K., Bookman, M. A., Cliby, W. A., Coleman, R. L., Dizon, D. S., Kash, J. J., Meyer, L. A., Moore, K. N., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.05.022 · Cited by 362
Self-citationNational Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer
Childers, C. P., Childers, K. K., Maggard-Gibbons, M., & Macinko, J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.6314 · Cited by 351
Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
du Bois, A., Floquet, A., Kim, J.-W., Rau, J., del Campo, J. M., Friedlander, M., Pignata, S., Fujiwara, K., Vergote, I., Colombo, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7348 · Cited by 328
Self-citationMonk, B. J., Poveda, A., Vergote, I., Raspagliesi, F., Fujiwara, K., Bae, D.-S., Oaknin, A., Ray-Coquard, I., Provencher, D. M., Karlan, B. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70244-x · Cited by 304
Self-citationTewari, D., Java, J. J., Salani, R., Armstrong, D. K., Markman, M., Herzog, T., Monk, B. J., & Chan, J. K. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.9898 · Cited by 288
Self-citationLedermann, J. A., Embleton, A. C., Raja, F., Perren, T. J., Jayson, G. C., Rustin, G. J. S., Kaye, S. B., Hirte, H., Eisenhauer, E., Vaughan, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01167-8 · Cited by 237
Walker, J. L., Brady, M. F., Wenzel, L., Fleming, G. F., Huang, H. Q., DiSilvestro, P. A., Fujiwara, K., Alberts, D. S., Zheng, W., Tewari, K. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01568 · Cited by 231
Self-citationNorquist, B. M., Brady, M. F., Harrell, M. I., Walsh, T., Lee, M. K., Gulsuner, S., Bernards, S. S., Casadei, S., Burger, R. A., Tewari, K. S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1327 · Cited by 230
Self-citationdu Bois, A., Kristensen, G., Ray-Coquard, I., Reuss, A., Pignata, S., Colombo, N., Denison, U., Vergote, I., del Campo, J. M., Ottevanger, P., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00366-6 · Cited by 211
Christie, E. L., Fereday, S., Doig, K., Pattnaik, S., Dawson, S.-J., & Bowtell, D. D. L. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.4627 · Cited by 196
Cohn, D. E., Kim, K. H., Resnick, K. E., O'Malley, D. M., & Straughn, J. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.1075 · Cited by 172
Rutten, M. J., van Meurs, H. S., van de Vrie, R., Gaarenstroom, K. N., Naaktgeboren, C. A., Gorp, T. V., ter Brugge, H. G., Hofhuis, W., Schreuder, H. W. R., Arts, H. J. G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.2962 · Cited by 148
Tewari, K. S., Java, J., Eskander, R. N., Monk, B. J., & Burger, R. A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv500 · Cited by 140
Self-citationBais, C., Mueller, B., Brady, M. F., Mannel, R. S., Burger, R. A., Wei, W., Marien, K. M., Kockx, M. M., Husain, A., Birrer, M. J., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx066 · Cited by 108
Self-citationColombo, N., Huang, G. S., Scambia, G., Chalas, E., Pignata, S., Fiorica, J. V., Le, L. V., Ghamande, S. A., González-Santiago, S., Bover, I., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.2781 · Cited by 106
Pignata, S., Scambia, G., Bologna, A., Signoriello, S., Vergote, I. B., Wagner, U. A. G., Lorusso, D., Murgia, V., Sorio, R., Ferrandina, G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.4293 · Cited by 87
Ferriss, J. S., Java, J., Bookman, M. A., Fleming, G. F., Monk, B. J., Walker, J. L., Homesley, H. D., Fowler, J. M., Greer, B. E., Boente, M. P., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.07.103 · Cited by 83
Self-citationFDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper
Herzog, T. J., Ison, G., Alvarez, R. D., Balasubramaniam, S., Armstrong, D. K., Beaver, J. A., Ellis, A., Tang, S. W., Ford, P., McKee, A., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.08.012 · Cited by 39
Self-citation
Cited by
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R., Fujiwara, K., Vergote, I., Colombo, N., Mäenpää, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911361 · Cited by 2,055
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Garcia, J., Hurwitz, H. I., Sandler, A. B., Miles, D., Coleman, R. L., Deurloo, R., & Chinot, O. L. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102017 · Cited by 1,159
Self-citationTreatment of epithelial ovarian cancer
Kuroki, L., & Guntupalli, S. R. (2020) · BMJ · doi:10.1136/bmj.m3773 · Cited by 873
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Barroilhet, L., Behbakht, K., Berchuck, A., Chen, L.-M., Cristea, M., DeRosa, M., Eisenhauer, E. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0007 · Cited by 715
Metadata
- Authors
- Tewari, K. S., Burger, R. A., Enserro, D., Norquist, B. M., Swisher, E. M., Brady, M. F., Bookman, M. A., Fleming, G. F., Huang, H., Homesley, H. D., Fowler, J. M., Greer, B. E., Boente, M., Liang, S. X., Ye, C., Bais, C., Randall, L. M., Chan, J. K., Ferriss, J. S., Coleman, R. L., Aghajanian, C., Herzog, T. J., DiSaia, P. J., Copeland, L. J., Mannel, R. S., Birrer, M. J., & Monk, B. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2019-09-10
- Volume
- 37
- Issue
- 26
- Pages
- 2317-2328
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2951714360
- Cited by
- 483
- References
- 35
- FWCI
- 46.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.